187 related articles for article (PubMed ID: 36845744)
41. Construction and validation of a bladder cancer risk model based on autophagy-related genes.
Shen C; Yan Y; Yang S; Wang Z; Wu Z; Li Z; Zhang Z; Lin Y; Li P; Hu H
Funct Integr Genomics; 2023 Jan; 23(1):46. PubMed ID: 36689018
[TBL] [Abstract][Full Text] [Related]
42. A Novel S100 Family-Based Signature Associated with Prognosis and Immune Microenvironment in Glioma.
Hu Y; Song J; Wang Z; Kan J; Ge Y; Wang D; Zhang R; Zhang W; Liu Y
J Oncol; 2021; 2021():3586589. PubMed ID: 34712325
[TBL] [Abstract][Full Text] [Related]
43. Identification of metabolism-related long non-coding RNA (lncRNA) signature predicts prognosis and immune infiltrates in hepatocellular carcinoma.
Wang X; Qian J; Yao N; Pocha C; Kang KJ; Angelico R; Zhu G
Ann Transl Med; 2022 May; 10(10):595. PubMed ID: 35722420
[TBL] [Abstract][Full Text] [Related]
44. A novel lactate metabolism-related signature predicts prognosis and tumor immune microenvironment of breast cancer.
Zhang Z; Fang T; Lv Y
Front Genet; 2022; 13():934830. PubMed ID: 36171887
[No Abstract] [Full Text] [Related]
45. A Novel lncRNA Panel Related to Ferroptosis, Tumor Progression, and Microenvironment is a Robust Prognostic Indicator for Glioma Patients.
He Y; Ye Y; Tian W; Qiu H
Front Cell Dev Biol; 2021; 9():788451. PubMed ID: 34950662
[No Abstract] [Full Text] [Related]
46. A novel disulfide death-related genes prognostic signature identifies the role of IPO4 in glioma progression.
Wu H; Yang Z; Chang C; Wang Z; Zhang D; Guo Q; Zhao B
Cancer Cell Int; 2024 May; 24(1):168. PubMed ID: 38734657
[TBL] [Abstract][Full Text] [Related]
47. Identification of the novel prognostic biomarker, MLLT11, reveals its relationship with immune checkpoint markers in glioma.
Chen L; Xiong Z; Zhao H; Teng C; Liu H; Huang Q; Wanggou S; Li X
Front Oncol; 2022; 12():889351. PubMed ID: 36033495
[TBL] [Abstract][Full Text] [Related]
48. Angiogenesis-related lncRNAs predict the prognosis signature of stomach adenocarcinoma.
Han C; Zhang C; Wang H; Li K; Zhao L
BMC Cancer; 2021 Dec; 21(1):1312. PubMed ID: 34876056
[TBL] [Abstract][Full Text] [Related]
49. A Prognostic DNA Damage Repair Genes Signature and Its Impact on Immune Cell Infiltration in Glioma.
Wang G; Zhou H; Tian L; Yan T; Han X; Chen P; Li H; Wang W; Xiao Z; Hou L; Xue X
Front Oncol; 2021; 11():682932. PubMed ID: 34123852
[TBL] [Abstract][Full Text] [Related]
50. Prognostic value of a microRNA signature as a novel biomarker in patients with lower-grade gliomas.
Qian Z; Li Y; Fan X; Zhang C; Wang Y; Jiang T; Liu X
J Neurooncol; 2018 Mar; 137(1):127-137. PubMed ID: 29204839
[TBL] [Abstract][Full Text] [Related]
51. Establishment and validation of a novel prognostic model for lower-grade glioma based on senescence-related genes.
Li J; Wang J; Liu D; Tao C; Zhao J; Wang W
Front Immunol; 2022; 13():1018942. PubMed ID: 36341390
[TBL] [Abstract][Full Text] [Related]
52. A specific immune signature for predicting the prognosis of glioma patients with IDH1-mutation and guiding immune checkpoint blockade therapy.
Zeng Z; Hu C; Ruan W; Zhang J; Lei S; Yang Y; Peng P; Pan F; Chen T
Front Immunol; 2022; 13():1001381. PubMed ID: 36159801
[TBL] [Abstract][Full Text] [Related]
53. Long non-coding RNA profile study identifies a metabolism-related signature for colorectal cancer.
Lu Y; Wang W; Liu Z; Ma J; Zhou X; Fu W
Mol Med; 2021 Aug; 27(1):83. PubMed ID: 34344319
[TBL] [Abstract][Full Text] [Related]
54. Constructing a signature based on the SIRT family to help the prognosis and treatment sensitivity in glioma patients.
Xuan F; Zhang Z; Liu K; Gong H; Liang S; Zhao Y; Li H
Front Genet; 2022; 13():1035368. PubMed ID: 36568393
[TBL] [Abstract][Full Text] [Related]
55. Characterization of a lactate metabolism-related signature for evaluation of immune features and prediction prognosis in glioma.
Wu Z; Wang J; Li Y; Liu J; Kang Z; Yan W
Front Neurol; 2022; 13():1064349. PubMed ID: 36698888
[TBL] [Abstract][Full Text] [Related]
56. Identification of prognostic gene signature associated with microenvironment of lung adenocarcinoma.
Yue C; Ma H; Zhou Y
PeerJ; 2019; 7():e8128. PubMed ID: 31803536
[TBL] [Abstract][Full Text] [Related]
57. Comprehensive exploration of tumor mutational burden and immune infiltration in diffuse glioma.
Kang K; Xie F; Wu Y; Wang Z; Wang L; Long J; Lian X; Zhang F
Int Immunopharmacol; 2021 Jul; 96():107610. PubMed ID: 33848908
[TBL] [Abstract][Full Text] [Related]
58. MCM4 is a novel prognostic biomarker and promotes cancer cell growth in glioma.
Yang S; Yuan Y; Ren W; Wang H; Zhao Z; Zhao H; Zhao Q; Chen X; Jiang X; Zhang L
Front Oncol; 2022; 12():1004324. PubMed ID: 36465369
[TBL] [Abstract][Full Text] [Related]
59. Autophagy related DNA methylation signature predict clinical prognosis and immune microenvironment in low-grade glioma.
Qiao Q; Wang Y; Zhang R; Pang Q
Transl Cancer Res; 2022 Jul; 11(7):2157-2174. PubMed ID: 35966301
[TBL] [Abstract][Full Text] [Related]
60. Construction and validation of a risk model based on the key SNARE proteins to predict the prognosis and immune microenvironment of gliomas.
Yin L; Xu Y; Yin J; Cheng H; Xiao W; Wu Y; Ji D; Gao S
Front Mol Neurosci; 2023; 16():1304224. PubMed ID: 38115820
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
